Patients with chronic pain from osteoarthritis who received LEVI-04 had a 50% reduction in pain from baseline. LEVI-04 was well...

Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma...

Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of...

Giroctocogene fitelparvovec, a novel gene therapy, demonstrated superiority to routine therapy in treating hemophilia A. Giroctocogene fitelparvovec resulted in a...

A dose-dependent slowing in Huntington's disease progression was observed after 24 months in patients receiving high-dose AMT-130. The gene therapy...

Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median...

83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control...

Patients on pemvidutide experienced only 21.9% of weight loss attributable to lean mass. Pemvidutide preserves muscle tissue and prioritizes fat...

Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution...

The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination...